Lebed Alert – ALQA will capture ENDP’s market share!

Recommended Stock Newsletters
 
#1. PennyStockWarfare
#2. Nova Stocks
#3. Penny Stock Finder

Jonathan Lebed Newsletter

I believe Alliqua (ALQA), currently just $0.155 with a market cap of $32 million, is positioned to capture a $1.4 billion market that is currently led by Endo Pharmaceuticals (ENDP), a $4.56 billion company.

Dr. Phillip Frost, who is on the Forbes list as a self-made billionaire with a net worth of $2.3 billion from pharmaceutical investments, just invested $1 million in ALQA! Dr. Frost is the Chairman of Teva Pharmaceutical (TEVA), a $40 billion company trading for $45 per share, and clearly he agrees with me that ALQA has the potential to capture ENDP`s market share! In the in vitro permeation study of ALQA`s pain patch product for postherpetic neuralgia (PHN), multiple formulations were evaluated, with some achieving mean cumulative drug permeation amounts much higher than the market leading product of ENDP, indicating the potential for an improvement over the existing product! ALQA is sitting on $1.756 million in cash and no debt, and that is NOT including Dr. Frost`s brand new $1 million investment into the company! Do you want to become a self-made billionaire In my opinion, the best way to become one is to invest where a self-made billionaire is investing! Never before have I seen a multi-billionaire invest heavily into a $0.155 stock! Although there are no sure things, ALQA is just about as close to a sure thing as I have ever discovered, especially in the pharmaceutical industry! I have been researching ALQA for over two years! A few years ago, this stock made a run from $0.22 to $5.80 and it wouldn`t surprise me to see ALQA make another huge run like this in the very near-future! Don`t doubt me about ALQA! Doubting me about ALQA will be just as big of a mistake as doubting me about silver! Read this Morningstar article about ENDP from April 11th: http://www.morningstar.ca/globalhome/industry/news.asparticleid6623 It says regarding ENDP`s PHN pain patch product, “Lidoderm brought in $783 million in sales in 2010, and Endo stands to lose the bulk of this revenue by 2015.” You know why ENDP, a $4.5 billion company, stands to lose the bulk of its $783 million in revenue they currently generate from Lidoderm Because of new improved competing products from companies like ALQA! —– My firm Lebed Biz LLC has been compensated by a third-party (Wall Street Grand, LLC) $25,000 cash for a one-month ALQA investor relations contract. We were not compensated for our previous coverage of ALQA back when the company traded under the symbol HPLF. Never invest into a stock we discuss unless you can afford to lose your entire investment. For our full disclaimer go to: http://lebed.biz/disclaimer.htm Jonathan Lebed Lebed.biz Staff This message was sent to from:

Jonathan Lebed | 350 Ramapo Valley Rd | Oakland, NJ 07436

 
This entry was posted in Jonathan Lebed and tagged , , , . Bookmark the permalink.

Comments are closed.